2025 Q3 -tulosraportti
47 päivää sittenTarjoustasot
Spotlight Stock Market DK
Määrä
Osto
50
Myynti
Määrä
1 412
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | AVA | NON | ||
| 17 | NON | NON | ||
| 1 942 | AVA | NON | ||
| 431 | AVA | NON | ||
| 300 | NON | NON |
Ylin
11,5VWAP
Alin
10,95VaihtoMäärä
0,8 69 378
VWAP
Ylin
11,5Alin
10,95VaihtoMäärä
0,8 69 378
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenModel update based on today's news. There is very good news regarding FPD AND that more patients have been enrolled. 1. What is the most important message in the announcement? The core is not “encouraging” or “first-in-class”. The core is: uTREAT shows clear, sustained tumor uptake in humans - with binding long enough to be able to deliver a relevant radiation dose. This is precisely the mechanism the entire case rests upon. 2. What has specifically been achieved (actual content) Target engagement in humans • “Clear and sustained uptake of uTREAT® in the tumor” • Confirms that uPAR-targeting works therapeutically, not just diagnostically. → This definitively closes TRIN 2 for the uTREAT part. Retention / binding kinetics • “Signal remained visible for at least 24 hours” • “Protracted binding kinetics” This is extremely important in radioligand therapy: • Short binding = low absorbed dose • Long binding = possibility for high Gy → This is the prerequisite for being able to reach 60 Gy without drastically escalating the dose. Dosimetry: “in line with expectations” • They deliberately do not state numbers (saved for NDA discussions) • But they clearly state: - not lower than expected - not problematic - not limiting → In practice, this means: • No negative surprise • No F1-falsification • The study continues unchanged 3. “Currently more patients are enrolled” (new and important detail) This is not a standard phrase – it has concrete significance: • FPD-data has been: o safe enough o biologically plausible enough o operationally unproblematic • There has been no need for: o pause o redesign o internal stop-and-review In practice, this means: FPD has passed the internal continuation threshold. Checklist: What does Curasight lack to resemble peers at the time of acquisition? Already fulfilled • Human target engagement (PET-uptake in GBM) • Prolonged retention (≥24h) • Theranostic consistency (uTRACE → uTREAT) • Active recruitment (no pause) • Platform logic (uPAR across tumors) Missing (exactly the same as peers were missing just before rerating) • Publicly quantified tumor-Gy • Documented organ margins (kidney/liver/bone marrow) • Early consistency (2–3 patients) • Reproducibility (TRIN 3c) When these are fulfilled, Curasight resembles peers at their time of acquisition – with lower target risk. Overall conclusion (short) • POINT, RayzeBio and Fusion were ALL acquired based on dosimetry in Phase I. • Curasight now has: o demonstrated target engagement and retention in humans o commenced TRIN 3a (more patients) • The next data point (Gy + organ margins = TRIN 3b/c) is precisely what historically triggered rerating and strategic interest. Exciting how the market reacts tomorrow, but it will come as a ketchup effect as data is communicated and since the stock is relatively illiquid without many free-floating shares. It is completely data-driven until TRIN 3 is fulfilled.
5 t sitten5 t sittenCurasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT® in High-Grade Gliomas Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma) Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors Copenhagen, 12th January, 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first patient dosed in ongoing Phase 1 clinical trial in patients with high-grade gliomas. Position emission tomography (PET)-images from the first treated patient showed clear and sustained uptake of uTREAT® in the tumor, confirming that the drug successfully targets cancer tissue. The signal remained visible for at least 24 hours, indicating prolonged tumor binding and supporting the potential for effective radiation delivery to the tumor. The patient’s PET signal persisted until the last PET scan (24 hours), demonstrating that uTREAT® has protracted binding kinetics, translating to a maximized tumor absorbed dose. These early results provide support for Curasight’s uPAR-targeted approach in radiopharmaceuticals and the potential of uTREAT® as a novel therapy for patients with high-grade gliomas and other uPAR expressing aggressive solid tumors (>85% of solid tumors). The preliminary dosimetry readout of uTREAT® was in line with expectations and supports to continue with additional GBM patients. Currently more patients are enrolled, and top-line data is expected in Q2 2026.
·6 t sittenIt was long.. 3 to 4 days.. oh well.. it looks good.. then we just need to sell the company at price 400..🤣🤣
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
47 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenModel update based on today's news. There is very good news regarding FPD AND that more patients have been enrolled. 1. What is the most important message in the announcement? The core is not “encouraging” or “first-in-class”. The core is: uTREAT shows clear, sustained tumor uptake in humans - with binding long enough to be able to deliver a relevant radiation dose. This is precisely the mechanism the entire case rests upon. 2. What has specifically been achieved (actual content) Target engagement in humans • “Clear and sustained uptake of uTREAT® in the tumor” • Confirms that uPAR-targeting works therapeutically, not just diagnostically. → This definitively closes TRIN 2 for the uTREAT part. Retention / binding kinetics • “Signal remained visible for at least 24 hours” • “Protracted binding kinetics” This is extremely important in radioligand therapy: • Short binding = low absorbed dose • Long binding = possibility for high Gy → This is the prerequisite for being able to reach 60 Gy without drastically escalating the dose. Dosimetry: “in line with expectations” • They deliberately do not state numbers (saved for NDA discussions) • But they clearly state: - not lower than expected - not problematic - not limiting → In practice, this means: • No negative surprise • No F1-falsification • The study continues unchanged 3. “Currently more patients are enrolled” (new and important detail) This is not a standard phrase – it has concrete significance: • FPD-data has been: o safe enough o biologically plausible enough o operationally unproblematic • There has been no need for: o pause o redesign o internal stop-and-review In practice, this means: FPD has passed the internal continuation threshold. Checklist: What does Curasight lack to resemble peers at the time of acquisition? Already fulfilled • Human target engagement (PET-uptake in GBM) • Prolonged retention (≥24h) • Theranostic consistency (uTRACE → uTREAT) • Active recruitment (no pause) • Platform logic (uPAR across tumors) Missing (exactly the same as peers were missing just before rerating) • Publicly quantified tumor-Gy • Documented organ margins (kidney/liver/bone marrow) • Early consistency (2–3 patients) • Reproducibility (TRIN 3c) When these are fulfilled, Curasight resembles peers at their time of acquisition – with lower target risk. Overall conclusion (short) • POINT, RayzeBio and Fusion were ALL acquired based on dosimetry in Phase I. • Curasight now has: o demonstrated target engagement and retention in humans o commenced TRIN 3a (more patients) • The next data point (Gy + organ margins = TRIN 3b/c) is precisely what historically triggered rerating and strategic interest. Exciting how the market reacts tomorrow, but it will come as a ketchup effect as data is communicated and since the stock is relatively illiquid without many free-floating shares. It is completely data-driven until TRIN 3 is fulfilled.
- 5 t sitten5 t sittenCurasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT® in High-Grade Gliomas Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma) Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors Copenhagen, 12th January, 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first patient dosed in ongoing Phase 1 clinical trial in patients with high-grade gliomas. Position emission tomography (PET)-images from the first treated patient showed clear and sustained uptake of uTREAT® in the tumor, confirming that the drug successfully targets cancer tissue. The signal remained visible for at least 24 hours, indicating prolonged tumor binding and supporting the potential for effective radiation delivery to the tumor. The patient’s PET signal persisted until the last PET scan (24 hours), demonstrating that uTREAT® has protracted binding kinetics, translating to a maximized tumor absorbed dose. These early results provide support for Curasight’s uPAR-targeted approach in radiopharmaceuticals and the potential of uTREAT® as a novel therapy for patients with high-grade gliomas and other uPAR expressing aggressive solid tumors (>85% of solid tumors). The preliminary dosimetry readout of uTREAT® was in line with expectations and supports to continue with additional GBM patients. Currently more patients are enrolled, and top-line data is expected in Q2 2026.
- ·6 t sittenIt was long.. 3 to 4 days.. oh well.. it looks good.. then we just need to sell the company at price 400..🤣🤣
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
50
Myynti
Määrä
1 412
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | AVA | NON | ||
| 17 | NON | NON | ||
| 1 942 | AVA | NON | ||
| 431 | AVA | NON | ||
| 300 | NON | NON |
Ylin
11,5VWAP
Alin
10,95VaihtoMäärä
0,8 69 378
VWAP
Ylin
11,5Alin
10,95VaihtoMäärä
0,8 69 378
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
47 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenModel update based on today's news. There is very good news regarding FPD AND that more patients have been enrolled. 1. What is the most important message in the announcement? The core is not “encouraging” or “first-in-class”. The core is: uTREAT shows clear, sustained tumor uptake in humans - with binding long enough to be able to deliver a relevant radiation dose. This is precisely the mechanism the entire case rests upon. 2. What has specifically been achieved (actual content) Target engagement in humans • “Clear and sustained uptake of uTREAT® in the tumor” • Confirms that uPAR-targeting works therapeutically, not just diagnostically. → This definitively closes TRIN 2 for the uTREAT part. Retention / binding kinetics • “Signal remained visible for at least 24 hours” • “Protracted binding kinetics” This is extremely important in radioligand therapy: • Short binding = low absorbed dose • Long binding = possibility for high Gy → This is the prerequisite for being able to reach 60 Gy without drastically escalating the dose. Dosimetry: “in line with expectations” • They deliberately do not state numbers (saved for NDA discussions) • But they clearly state: - not lower than expected - not problematic - not limiting → In practice, this means: • No negative surprise • No F1-falsification • The study continues unchanged 3. “Currently more patients are enrolled” (new and important detail) This is not a standard phrase – it has concrete significance: • FPD-data has been: o safe enough o biologically plausible enough o operationally unproblematic • There has been no need for: o pause o redesign o internal stop-and-review In practice, this means: FPD has passed the internal continuation threshold. Checklist: What does Curasight lack to resemble peers at the time of acquisition? Already fulfilled • Human target engagement (PET-uptake in GBM) • Prolonged retention (≥24h) • Theranostic consistency (uTRACE → uTREAT) • Active recruitment (no pause) • Platform logic (uPAR across tumors) Missing (exactly the same as peers were missing just before rerating) • Publicly quantified tumor-Gy • Documented organ margins (kidney/liver/bone marrow) • Early consistency (2–3 patients) • Reproducibility (TRIN 3c) When these are fulfilled, Curasight resembles peers at their time of acquisition – with lower target risk. Overall conclusion (short) • POINT, RayzeBio and Fusion were ALL acquired based on dosimetry in Phase I. • Curasight now has: o demonstrated target engagement and retention in humans o commenced TRIN 3a (more patients) • The next data point (Gy + organ margins = TRIN 3b/c) is precisely what historically triggered rerating and strategic interest. Exciting how the market reacts tomorrow, but it will come as a ketchup effect as data is communicated and since the stock is relatively illiquid without many free-floating shares. It is completely data-driven until TRIN 3 is fulfilled.
- 5 t sitten5 t sittenCurasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT® in High-Grade Gliomas Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma) Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors Copenhagen, 12th January, 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first patient dosed in ongoing Phase 1 clinical trial in patients with high-grade gliomas. Position emission tomography (PET)-images from the first treated patient showed clear and sustained uptake of uTREAT® in the tumor, confirming that the drug successfully targets cancer tissue. The signal remained visible for at least 24 hours, indicating prolonged tumor binding and supporting the potential for effective radiation delivery to the tumor. The patient’s PET signal persisted until the last PET scan (24 hours), demonstrating that uTREAT® has protracted binding kinetics, translating to a maximized tumor absorbed dose. These early results provide support for Curasight’s uPAR-targeted approach in radiopharmaceuticals and the potential of uTREAT® as a novel therapy for patients with high-grade gliomas and other uPAR expressing aggressive solid tumors (>85% of solid tumors). The preliminary dosimetry readout of uTREAT® was in line with expectations and supports to continue with additional GBM patients. Currently more patients are enrolled, and top-line data is expected in Q2 2026.
- ·6 t sittenIt was long.. 3 to 4 days.. oh well.. it looks good.. then we just need to sell the company at price 400..🤣🤣
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
50
Myynti
Määrä
1 412
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | AVA | NON | ||
| 17 | NON | NON | ||
| 1 942 | AVA | NON | ||
| 431 | AVA | NON | ||
| 300 | NON | NON |
Ylin
11,5VWAP
Alin
10,95VaihtoMäärä
0,8 69 378
VWAP
Ylin
11,5Alin
10,95VaihtoMäärä
0,8 69 378
Välittäjätilasto
Dataa ei löytynyt